case_images: PMC9884833_01
case_images: PMC9884833_02
case_images: Depressive and anxiety symptoms scores at recruitment point and during 20 months of active DBS stimulation period. HAMA, Hamilton Anxiety Rating Scale; HDRS-17, Hamilton Depression Rating Scale 17-item version; MADRS, Montgomery-Asberg Depressive Rating Scale.
case_images: fpsyt-13-1068054-g0002.jpg
case_images: PMC9884833_02_fpsyt-13-1068054-g0002.jpg
case_images: F2
case_images: The patient also reported improvement in self-assessment VAS scales (see Figure 2). A sudden relapse of symptoms with subjective worsening of mental state (see Figure 2) and stimulation side effects were reported (hand tremors, tachycardia, vision blurring and diplopia).
case_images: SOFAS (Social and Occupational Functioning Assessment Scale) scores at recruitment point and during 20 months of active DBS stimulation period.
case_images: fpsyt-13-1068054-g0003.jpg
case_images: PMC9884833_02_fpsyt-13-1068054-g0003.jpg
case_images: F3
case_images: Visual analog scale (VAS) of self-assessment scores at recruitment point and during 20 months of active DBS stimulation period. Mood and concentration scales were scored positively (0-worst mood and concentration and 10-best mood and concentration), while anxiety and physical discomfort scales were scored negatively (0-least intensive anxiety and discomfort and 10-most intensive anxiety and discomfort).
case_images: fpsyt-13-1068054-g0004.jpg
case_images: PMC9884833_02_fpsyt-13-1068054-g0004.jpg
case_images: F4
case_images: See Figure 4 for more details.
case_images: Timeline of the treatment.
case_images: fpsyt-13-1068054-g0005.jpg
case_images: PMC9884833_02_fpsyt-13-1068054-g0005.jpg
case_images: F5
case_images: For detailed information on the treatment timeline, please see Figure 5.